What is the survival rate of EGFR-positive lung cancer? The life expectancy for someone with EGFR-positive lung cancer varies depending on things such as age at diagnosis, the stage of cancer, and overall health. However, new drugs can help improve survival times. For example, a recent study...
[13]YANG J C H, WU Y L, SCHULER M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two rand...
unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial) [J]. Thorac Cancer. 2022 Dec;13(23):3431-3435. doi: 10.1111
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer(FURLONG): a multicentre,double-blind,randomised phase 3 study[J]. Lancet Respir Med,2022,10(11):1019-1028. [15] SHI Y K...
Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer Latest CME Events & Activities Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care View More Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management View More ...
英文摘要: OBJECTIVE:To evaluate the economic s of osimertinib versus first-generation EGFR-TKIs in the first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC),and to provide evidence-based reference for medical and healthy decision-making in ...
Nishio M, et al.Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment foradvanced EGFR mutation-positive non-squamous non-small-cell lung cancer:Survival follow-up results of the randomized JO25567 study. Lung Cancer. 2020Nov 20;151:20-24. doi: 10.1016/j.lungcan.2020.11....
参考文献:Okamoto I, Morita S, et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer. 2018 Mar; 117:14-19. 专家简介 任胜祥 同济大学附属上海市肺科医院 ...
参考文献:Okamoto I, Morita S, et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer. 2018 Mar; 117:14-19. 专家简介 任胜祥 同济...
非小细胞肺癌(non-small cell lung cancer,NSCLC)是最常见的肺癌类型,约占肺癌的 82%。NSCLC 靶向治疗的重大进展显著提高了客观缓解率(objective response rate,ORR)及生存质量,同时延长了患者的无进展生存时间(progression-free surviva...